PHOENIX, July 2025’ Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a clinical-stage biotechnology firm focused on regenerative medicine, has announced significant developments in the prevention and treatment of Type 1 Diabetes (T1D) and in the field of AI-driven medical diagnostic programs.
On July 17, 2025, the company received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent application
Sources for this article: Based on Creative Medical Technology Holdings Inc ’s official statement and
CSIMarket.com Customer Analytics Research for Creative Medical Technology Holdings Inc
For details on how CSIMarket validates financial and corporate news, please review our
Editorial Standards & Fact-Checking Policy
.
Comments